Twenty-one years is a long time to hold one job at one site. It is long enough to watch a company move from research into commercial manufacturing, and long enough to see quality get redefined by every leadership team that walks through the door.
That was the starting point of a conversation I had the privilege of moderating this week: a fireside chat with Frank Mottola, SVP and Chief Technical Operations Officer at Supernus Pharmaceuticals, as part of BioBuzz Networks' "Built to Scale" series. The premise of the evening was operational infrastructure. The real subject, once Frank started talking, was something harder to build and easier to lose: what quality actually costs an organization when leadership stops treating it as a discipline and starts treating it as a line item.
We are living through a moment where AI adoption gets used as cover for cost-cutting, and quality departments are an easy target. Reduce headcount, call it efficiency, and hope the systems hold. They do not hold. Not because the technology fails, but because quality was never overhead to begin with. It is the bridge between what a company builds and what a regulator, a patient, or a competitor can actually trust. Cut the bridge and call it a bridge anyway, and eventually somebody finds out the hard way.
Frank's twenty-one years gave him a different vantage point than most panels offer: not a consultant's view of validation, but an operator's memory of every place the discipline slipped and what it cost to rebuild it. The conversation moved through failure as a leadership skill rather than a personal flaw, through what it takes to build a team that admits mistakes early instead of burying them, and through a plain observation that growth means nothing to the people doing the work if their own career story disappears inside it.
None of that is new to anyone who has run a quality organization through a scale-up. What was notable was hearing it said out loud, on a stage, without the hedging that usually accompanies this topic in public. That is the value BioBuzz built into this series, and it is the same discipline I brought to the room representing ProcellaRX and the AI-GMP Training Accelerator we are building with BioBuzz for Maryland's life sciences workforce: name the dysfunction directly, or the industry keeps rediscovering it the expensive way.
The rest of the evening carried the same thread through different rooms: Arthur Edge III (AstraZeneca) and the honest math of outsourcing to a CDMO; Matt Dillon’s interview with Priyesh Madagaut (Samsung Biologics) on what facility scalability actually requires before a company is ready to claim it; and Stephen Perry (Kymanox) on supply chain resilience at a moment when domestic dual-sourcing stopped being a hedge and became policy. Different systems, same underlying question: does the infrastructure hold when nobody is watching, or does it only look built to scale?
Quality is not overhead. It is not a gate standing between a company and its next milestone. It is the bridge that decides whether the milestone means anything once you get there.